Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice.
Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice.
复制标题
DOI：
10.1182/blood.v90.1.85.85_85_96
复制
发表时间：
1997-07
期刊：
影响因子：
20.3
通讯作者：
C. Hogan;E. Shpall;Oren McNulty;I. Mcniece;J. Dick;L. Shultz;G. Keller
中科院分区：
文献类型：
--
作者：
C. Hogan;E. Shpall;Oren McNulty;I. Mcniece;J. Dick;L. Shultz;G. Keller
了解人类造血干细胞/祖细胞部分的再增殖特征对于预测其在高剂量治疗后移植到高风险患者中后的表现至关重要。我们报道，人脐带血细胞（其中 78% 至 100% 表达造血祖细胞表面标记 CD34）可以在亚致死照射的 NOD/LtSz-scid/scid 小鼠的造血组织中持续移植、发育和增殖。 CD34+细胞的植入和发育不依赖于人类生长因子的支持。 CD34+ 细胞归巢于小鼠骨髓 (BM)，该骨髓成为人类造血发育的主要部位，包含骨髓、淋巴、红细胞和 CD34+ 祖细胞群。骨髓细胞，特别是具有更成熟细胞表面标志物的淋巴细胞，包含小鼠脾脏和外周血的人类成分，表明发育从初级造血部位到外周进行。通过来自初级受体的BM用人类细胞对次级受体进行再增殖表明输入前体群体维持了显着的增殖能力。这些数据表明，CD34+细胞组分中含有能够启动人类细胞植入的细胞（SCID再生细胞），并且该小鼠模型将可用于测定其他稀有人类造血细胞组分的体内发育潜力。
Understanding the repopulating characteristics of human hematopoietic stem/progenitor cell fractions is crucial for predicting their performance after transplant into high-risk patients following high-dose therapy. We report that human umbilical cord blood cells, 78% to 100% of which express the hematopoietic progenitor cell surface marker CD34, can consistently engraft, develop, and proliferate in the hematopoietic tissues of sublethally irradiated NOD/LtSz-scid/scid mice. Engraftment and development of CD34+ cells is not dependent on human growth factor support. CD34+ cells home to the mouse bone marrow (BM) that becomes the primary site of human hematopoietic development containing myeloid, lymphoid, erythroid, and CD34+ progenitor populations. Myeloid, and in particular lymphoid cells possessing more mature cell surface markers, comprise the human component of mouse spleen and peripheral blood, indicating that development proceeds from primary hematopoietic sites to the periphery. Repopulation of secondary recipients with human cells by BM from primary recipients demonstrates the maintenance of substantial proliferation capacity of the input precursor population. These data suggest that the cells capable of initiating human cell engraftment (SCID-repopulating cells) are contained in the CD34+ cell fraction, and that this mouse model will be useful for assaying the developmental potential of other rare human hematopoietic cell fractions in vivo.